Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2012

View Archived Issues

Novartis reports novel CDK9 inhibitors

First prenatal replacement therapy presented for rare form of dystonia

Biotherapy demonstrates activity relevant to multiple sclerosis

New in vivo data disclosed on monomethylfumarate prodrug for MS

ETS-2101 trial in brain cancer begins enrollment

German group discloses new agents for dermatological disorders

Novel products for tuberculosis designed at Sanofi

AstraZeneca stops AZD-2820 study

Novel agents for AIDS prepared at Pfizer

Canadian study investigates microglial activation in patients with PD

Phase III crizotinib study meets endpoint

NewLink updates enrollment information for algenpantucel-L trial

Galaxy Biotech regains worldwide rights to antibody for cancer

Zalicus completes phase I study of Z-944

Novelos reports imaging results with [124I]-CLR-1404 in brain cancer

Investigational gene therapy gets orphan drug status for adrenoleukodystrophy

Jenrin Discovery develops new agents targeting CB1 receptor

AstraZeneca and Rigel sign worldwide licensing agreement for asthma drug

French center synthesizes new agents for bone disorders

Team in Israel patents new treatments for genetic disorders

Vaxin receives phase I SBIR grant to support development of anthrax vaccine

Wellcome Trust supports development of nontyphoidal Salmonella conjugate vaccine

EMA validates MAAs for fixed-dose combination diabetes therapies

First clinical data disclosed on Genzyme DNA topoisomerase I inhibitor

EpiCept sells European rights for Ceplene to Meda

Viamet and NIAID enter agreement to advance new class of broad-spectrum antifungals

Novel candidate hepatitis therapies divulged by Gilead Sciences

Heptares and U.K. Medical Research Council extend collaboration

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...